Announcements
OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (supplement base date)
1.Type of merger and acquisition (e.g. merger, spin-off, acquisition, or share transfer): Share transfer 2.Date of occurrence of the event: Nov 27, 2020 3.Names of companies participating in the merger …
OBI received the reply from FDA about the Investigational Device Exemption (IDE) of Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424
1. Date of occurrence of the event: Nov 23, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4. …
Announcement of 2020 Q3 financial reports submitted to the board of directors
Date of the financial reports submitted to the board of directors or approved by the board of directors: Nov 06, 2020 Date of the financial reports approved by the audit …
OBI capital increases by issuance of stocks to transfer stocks with Amaran Biotechnology Inc. (the agreement of share exchange and cooperation signed, and trading counterparts designated)
1. Type of merger and acquisition (e.g. merger, spin-off, acquisition, or share transfer): Share transfer 2. Date of occurrence of the event: Oct 15, 2020 3. Names of companies participating …
OBI filed an application of Investigational Device Exemption (IDE) for Phase I/II Cohort Expansion human clinical studies for first-in-class novel prodrug, OBI-3424, to FDA
1. Date of occurrence of the event: Oct 06, 2020 2. Company name: OBI Pharma Inc. 3. Relationship to the Company (please enter “head office” or “subsidiaries”): head office 4. …
OBI capital increases by issuance of stocks as the consideration of share exchange cooperation with Amaran Biotechnology Inc.
1. Type of merger and acquisition (e.g. merger, spin-off, acquisition, or share transfer): Share transfer 2. Date of occurrence of the event: Sep 28, 2020 3. Names of companies participating …
Announcement of press release of press conference on Sept 28, 2020
1. Date and time that the Company disclose its financial or business information to the public: 8 pm on Sep 28, 2020 2. Location that the Company disclose its financial …
Board of directors resolved to license DNA sequence of OBI-888 to AP Bioscience Inc. for bispecific antibody development
Date of occurrence of the event: Sep 28, 2020 Company name: OBI Pharma Inc Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: Not …
Board of directors’ resolution on licensing of OBI-833, OBI-888 and OBI-999 in China (including Hong Kong and Macao)
Date of occurrence of the event: Sep 28, 2020 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): head office Reciprocal shareholding ratios: not applicable …
New Appointment of Compensation Committee Member
Date of occurrence of the change: Sep 28, 2020 Name of the functional committees: Compensation committee Name and resume of the previous position holder: Chung-Ming Chang Honorary Research Fellow of …